R.P. Boggs & Co. Regeneron Pharmaceuticals, Inc. Transaction History
R.P. Boggs & Co.
- $150 Million
- Q4 2024
A detailed history of R.P. Boggs & Co. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, R.P. Boggs & Co. holds 9,279 shares of REGN stock, worth $6.26 Million. This represents 4.41% of its overall portfolio holdings.
Number of Shares
9,279
Previous 8,896
4.31%
Holding current value
$6.26 Million
Previous $9.35 Million
29.32%
% of portfolio
4.41%
Previous 6.36%
Shares
16 transactions
Others Institutions Holding REGN
# of Institutions
1,487Shares Held
83.4MCall Options Held
1.32MPut Options Held
1.52M-
Vanguard Group Inc Valley Forge, PA9.29MShares$6.26 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.7 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.06MShares$4.76 Billion0.41% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.31 Billion0.21% of portfolio
-
Capital International Investors Los Angeles, CA4.74MShares$3.19 Billion0.66% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $72.3B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...